ACXP Stock Forecast: Acurx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.02
−0.97% on the day

The median 12-month analyst price target for Acurx Pharmaceuticals, Inc. is $10. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$6.2M
Ticker Nerd rank
18/ 100
Median analyst target
$10
Analysts covering
3
Revenue$0.0
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$1.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.3%
1M
−10.5%
YTD
−59.0%
1Y
−73.9%
From 52W high
−84.6%
From 52W low
+9.1%
$0.94
$6.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Acurx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
18/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
63
Quality
45
Growth
41
Accruals
34
Issuance
23
Revisions
21
Value
17
Momentum
14

Volatility (63): The share price has been relatively steady.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26ACXPHigh $11Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$10
Low
$10
Median
$11
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Nov 2026HC Wainwright & Co.MaintainsBuy$31 → $11
29 Sept 2026HC Wainwright & Co.ReiteratesBuy$31
30 Sept 2025HC Wainwright & Co.ReiteratesBuy$31
12 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025HC Wainwright & Co.AssumesBuy$8.00
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
19 Mar 2024HC Wainwright & Co.MaintainsBuy—
28 Feb 2024HC Wainwright & Co.ReiteratesBuy—
15 Dec 2023HC Wainwright & Co.MaintainsBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—
13 Sept 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.MaintainsBuy—
15 May 2023HC Wainwright & Co.ReiteratesBuy—
11 Apr 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACXP.

Market Radar

This page is one stock. Monday covers all of them.

ACXP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACXP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Acurx Pharmaceuticals, Inc. returned −73.9% against +6.9% for the S&P 500, dividends included.

ACXP vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26ACXPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−147.5%

Higher than 10% of US stocks

Return on assets
−62.9%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acurx Pharmaceuticals, Inc. has a market value of $6.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$7.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.2M.

  • Shares outstanding: 4.3M.

  • Acurx Pharmaceuticals, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ACXP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACXPAcurx Pharmaceuticals, Inc.$6.2M18
KYNBKyntra Bio, Inc.$6.3M41
FBLGFibroBiologics, Inc.$6.3M64
CNSYCerenome, Inc.$6.2M13
GTBPGT Biopharma, Inc.$6.1M13
ENVBEnveric Biosciences, Inc.$6.0M16
MTVAMetaVia, Inc.$6.7M10

Take a look at ACXP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Acurx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ACXP

What is the ACXP stock price forecast for 2026-2027?

The median 12-month analyst price target for Acurx Pharmaceuticals, Inc. is $10, with estimates ranging from $10 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACXP stock a buy right now?

Of the 3 analysts covering Acurx Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acurx Pharmaceuticals, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACXP?

As at 21 Nov 2026, Acurx Pharmaceuticals, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (63 of 100).

Will ACXP stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $10, and Ticker Nerd's factor model ranks Acurx Pharmaceuticals, Inc. 18 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACXP stock forecast for 2030?

No analyst covering Acurx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $11 over the next 12 months.

How has ACXP stock performed over the past year?

Acurx Pharmaceuticals, Inc. returned -73.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acurx Pharmaceuticals, Inc. do?

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections. Acurx Pharmaceuticals Inc. develops small-molecule therapies designed to target Gram-positive pathogens through a distinct mechanism of action, with its lead candidate ibezapolstat aimed at infections such as Clostridium difficile.

Company

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections. Acurx Pharmaceuticals Inc. develops small-molecule therapies designed to target Gram-positive pathogens through a distinct mechanism of action, with its lead candidate ibezapolstat aimed at infections such as Clostridium difficile. The company is also advancing ACX-375C, an antibiotic program intended to address resistant bacteria including MRSA, VRE, and drug-resistant Streptococcus pneumoniae. In addition to its lead and pipeline candidates, Acurx Pharmaceuticals Inc. works on anti-infective therapies for pathogens identified as priority threats by major public health agencies. The company operates in the biopharmaceutical sector, where its research is centered on unmet medical needs in infectious disease treatment and the development of new options for antibiotic-resistant infections.

CEO Mr. David P. Luci CPA, Esq., J.D. · 4 employees · United States · https://www.acurxpharma.com